Zihua Zou

Fuzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Journal: Translational lung cancer research
Published: October 09, 2025

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

Journal: Thoracic cancer
Published: August 30, 2025

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.

Journal: MedComm
Published: July 30, 2025

Early Local Treatment Delays Multiple Metastases in Non-Small Cell Lung Cancer With Solitary Distant Metastasis: A Multicenter Retrospective Cohort Study.

Early Local Treatment Delays Multiple Metastases in Non-Small Cell Lung Cancer With Solitary Distant Metastasis: A Multicenter Retrospective Cohort Study.

Journal: MedComm
Published: July 15, 2025

Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.

Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.

Journal: Thoracic cancer
Published: April 19, 2025

A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.

A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.

Journal: Thoracic cancer
Published: March 24, 2025

Expert consensus on cancer treatment-related lung injury.

Expert consensus on cancer treatment-related lung injury.

Journal: Journal of thoracic disease
Published: February 12, 2025

Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.

Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: January 06, 2025

Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.

Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.

Journal: Thoracic cancer
Published: November 03, 2024

Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.

Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.

Journal: Journal of translational medicine
Published: April 23, 2024

Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Journal: Therapeutic advances in medical oncology
Published: December 12, 2023

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Journal: Thoracic cancer
Published: November 27, 2023
Showing 1-12 of 23

Last Updated: 09/26/2026